


WHAT IS CLAIMED IS:

1. A compound having formula (I):



an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug or a complex thereof, wherein:

X¹ is selected from the group consisting of nitrogen and CH;

R^{1a} is selected from the group consisting of hydrogen, halogen, CF₃, OCF₃, C₁₋₄ linear alkyl, C₃₋₄ branched alkyl, (C₂₋₈ dialkylamino)(C₂₋₄ alkyl), (C₃₋₆ alkyleneamino)(C₂₋₄ alkyl), C₁₋₄ linear alkoxy, and C₃₋₄ branched alkoxy;


R^{1b} is selected from the group consisting of hydrogen, halogen, CF₃, OCF₃, C₁₋₄ linear alkyl, C₃₋₄ branched alkyl, (C₂₋₈ dialkylamino)(C₂₋₄ alkyl), (C₃₋₆ alkyleneamino)(C₂₋₄ alkyl), C₁₋₄ linear alkoxy, and C₃₋₄ branched alkoxy;


R^{1c} is selected from the group consisting of hydrogen, halogen, CF₃, OCF₃, C₁₋₄ linear alkyl, C₃₋₄ branched alkyl, (C₂₋₈ dialkylamino)(C₂₋₄ alkyl), (C₃₋₆ alkyleneamino)(C₂₋₄ alkyl), C₁₋₄ linear alkoxy, and C₃₋₄ branched alkoxy;

R^{1d} is selected from the group consisting of hydrogen, halogen, CF₃, OCF₃, C₁₋₄ linear alkyl, C₃₋₄ branched alkyl, (C₂₋₈ dialkylamino)(C₂₋₄ alkyl), (C₃₋₆ alkyleneamino)(C₂₋₄ alkyl), C₁₋₄ linear alkoxy, and C₃₋₄ branched alkoxy;

wherein any two selected from the group consisting of R^{1a}, R^{1b}, R^{1c}, and R^{1d} are optionally connected to form a ring;


R² is selected from the group consisting of $-(CH_2)_n-NR^5R^6$, $-(CH_2)_nC(O)-NR^5R^6$,









n^1 is 1 or 2;


R⁴ is hydrogen; CF₃; a five-membered monocyclic heteroaryl ring comprising at least one heteroatom selected from the group consisting from O, N, and S that is optionally substituted with up to 2 groups selected from C₁₋₄ linear alkyl, C₃₋₄ branched alkyl, C₁₋₄ linear




heteroatom selected from the group consisting from O, N, and S;



,
 ,
 ,
 a phenyl ring that is optionally substituted with up to 2 groups selected from C₁₋₄ linear alkyl, C₃₋₄ branched alkyl, C₁₋₄ linear alkoxy, C₃₋₄ branched alkoxy, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkoxy, CF₃, CF₃O, halogen,






R^{3a} is at each occurrence independently selected from the group consisting of C_{1-4} linear alkyl and C_{3-4} branched alkyl;


R^{3b} is at each occurrence independently selected from the group consisting of C_{1-4} linear alkyl and C_{3-4} branched alkyl;

R^5 is selected from the group consisting of hydrogen, C_{1-4} linear alkyl, C_{3-4} branched alkyl, $-CH_2-(C_{1-6}$ cycloalkyl), $C(O)C_{1-6}$ linear alkyl, $C(O)C_{3-6}$ branched alkyl,

$C(O)CH(NH_2)C_{1-6}$ linear alkyl, $C(O)CH(NH_2)C_{3-6}$ branched alkyl,




R^6 is selected from the group consisting of C_{1-4} linear alkyl, C_{3-4} branched alkyl,



and an optionally substituted benzyl group wherein the optionally substituted benzyl group is substituted with 0

to 2 groups selected from the group consisting of halogen, $-\text{CN}$, $-\text{NO}_2$, $-\text{OH}$, $-\text{NH}_2$, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, C_{3-7} cycloalkyl, aryl,

heterocycle, and heteroaryl, provided that when R^2 is , R^6 is not hydrogen, C_{1-4} linear alkyl, C_{3-4} branched alkyl, or benzyl;

n^2 is 1 or 2;

n^3 is 0 or 1;

n^4 is 0 or 1;

n^5 is 0, 1, or 2;

n^6 is 0 or 1;


R^7 is selected from the group consisting of hydrogen and $\text{C}(\text{O})\text{OR}^8$;

R^8 is selected from the group consisting of C_{1-4} linear alkyl and C_{3-4} branched alkyl;

X^2 is selected from the group consisting of a single bond, oxygen, CH_2 , CHOH , and NR^9 ;

R^9 is C_{1-4} linear alkyl that is optionally substituted with an NH_2 ;

R^{10} is selected from the group consisting of OH , OR^{11} , $\text{NR}^{12}\text{R}^{13}$, $\text{NHSO}_2\text{R}^{22}$, and




R^{11} is selected from the group consisting of C_{1-4} linear alkyl and C_{3-4} branched alkyl;

R^{12} is selected from the group consisting of hydrogen, C_{1-4} linear alkyl, C_{3-4} branched alkyl, C_{1-4} linear fluoroalkyl, $\text{C}(\text{O})\text{R}^{14}$;

R^{13} is selected from the group consisting of hydrogen, C_{1-4} linear alkyl, C_{3-4} branched alkyl, and heteroaryl;

R^{12} and R^{13} are optionally taken together with the atoms to which they are connected to form a ring with 3 to 6 atoms;

R^{14} is selected from the group consisting of C_{1-4} linear alkyl C_{3-4} branched alkyl, and



R^{15} is selected from the group consisting of C_{1-4} linear alkyl and C_{3-4} branched alkyl;

R^{16} is selected from the group consisting of hydrogen, C_{1-4} linear alkyl, C_{3-4} branched alkyl, $CH_2-(C_{1-6}$ cycloalkyl), and $C(O)R^{18}$;

R^{17} is selected from the group consisting of hydrogen, benzyl and $C(O)R^{18}$;


R^{18} is selected from the group consisting of C_{1-4} linear alkyl and C_{3-4} branched alkyl;

R^{19} is selected from the group consisting of hydrogen and $C(O)R^{20}$;

R^{20} is selected from the group consisting of C_{1-4} linear alkyl and C_{3-4} branched alkyl;

R^{21} is a benzene ring that is optionally substituted with 0 to 2 groups selected from the group consisting of halogen, $-CN$, $-NO_2$, $-OH$, $-NH_2$, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, C_{3-7} cycloalkyl, aryl, heterocycle, and heteroaryl;

R^{22} is selected from the group consisting of C_{1-4} linear alkyl, C_{3-4} branched alkyl,



n is 2, 3, or 4;

m is 2, 3, or 4;

q is 2, 3, or 4;

y is 2, 3, or 4;

u is 2, 3, or 4;

v is 2, 3, or 4;


w is 2, 3, or 4;

z is 1, 2 or 3;

r is 2, 3, or 4; and


x is 2, 3, or 4.

2. The compound of claim 1 having formula (II):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

3. The compound of claim 1 having formula (III):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

4. The compound of claim 1 having formula (IV):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

5. The compound of claim 1 having formula (V):




,
an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt,
an isotopic analog, a prodrug, or a complex thereof.

6. The compound of claim 1 having formula (VI):




,
an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt,
an isotopic analog, a prodrug, or a complex thereof.

7. The compound of claim 1 having formula (VII):




,
an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt,
an isotopic analog, a prodrug, or a complex thereof.

8. The compound of claim 1 having formula (VIII):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

9. The compound of claim 1 having formula (IX):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

10. The compound of claim 1 having formula (X):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

11. The compound of claim 1 having formula (XI):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, and a complex thereof.

12. The compound of claim 1 having formula (XII):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

13. The compound of claim 1 having formula (XIII):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

14. The compound of claim 1 having formula (XIV):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrugs, or a complex thereof.

15. The compound of claim 1 having formula (XV):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

16. The compound of claim 1 having formula (XVI):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

17. The compound of claim 1 having formula (XVII):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

18. The compound of claim 1 having formula (XVIII):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salts, an isotopic analog, a prodrug, or a complex thereof.

19. The compound of claim 1 having formula (XIX):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

20. The compound of claim 1 having formula (XX):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

21. The compound of claim 1 having formula (XXI):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

22. The compound of claim 1 having formula (XXII):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complexes thereof.

23. The compound of claim 1 having formula (XXIII):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

24. The compound of claim 1 having formula (XXIV):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

25. The compound of claim 1 having formula (XXV):




an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analogs, a prodrug, or a complex thereof.

26. The compound of claim 1 having formula (XXVI):



an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

27. The compound of claim 1 having formula (XXVII):



an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

28. The compound according to claim 1 that is:

N^1 -(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)- N^1, N^3, N^3 -trimethyl propane-1,3-diamine;
 2-(4-Methoxyphenyl)-N-(3-{methyl[3-(methylamino)propyl]-amino}propyl)quinolin-4-amine;
 N^1 -(3-Aminopropyl)- N^3 -(2-(4-methoxyphenyl)quinolin-4-yl)- N^1 -methylpropane-1,3-diamine;
 N^1 -(2-(4-Methoxyphenyl)quinolin-4-yl)- N^3 -(3-(piperidin-1-yl)propyl)propane-1,3-diamine;
 N^1 -(2-(4-methoxyphenyl)quinolin-4-yl)- N^3 -methyl- N^3 -(3-(piperidin-1-yl)propyl)propane-1,3-diamine;

tert-Butyl N-{3-[(3-{[2-(4-methoxyphenyl)quinolin-4-yl]amino}propyl)amino]propyl} carbamate;
 N¹-(3-aminopropyl)-N³-(5-fluoro-2-(4-methoxyphenyl)quinolin-4-yl)-N¹-methylpropane-1,3-diamine;
 N-{3-[(3-Aminopropyl)amino]propyl}-2-(4-methoxyphenyl)quinolin-4-amine;
 N¹-(3-Aminopropyl)-N³-(6-methoxy-2-(4-methoxyphenyl)quinolin-4-yl)-N¹-methylpropane-1,3-diamine;
 N¹-(3-Aminopropyl)-N³-(2-(2-methyl-4-methoxyphenyl)quinolin-4-yl)-N¹-methylpropane-1,3-diamine;
 N¹-(3-Aminopropyl)-N³-(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)-N¹-methylpropane-1,3-diamine;
 N¹-(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)-N¹,N⁴-dimethylbutane-1,4-diamine;
 N¹-(2-fluoroethyl)-N³-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)-N¹,N³-dimethylpropane-1,3-diamine;
 3-((3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)amino)-propan-1-ol;
 N-(3-(3-methoxypropylamino)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;
 N-(3-(2-(4-Methoxyphenyl)quinolin-4-ylamino)propyl)-N-(3-aminopropyl)acetamide;
 N¹-(Cyclopropylmethyl)-N¹-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)-N³,N³-dimethyl propane-1,3-diamine;
 tert-Butyl 3-(((3-(dimethylamino)propyl)(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl) amino)methyl)azetidine-1-carboxylate;
 tert-Butyl 4-(((3-(dimethylamino)propyl)(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl) amino)methyl)piperidine-1-carboxylate;
 N¹-(Azetidin-3-ylmethyl)-N¹-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)-N³,N³-dimethylpropane-1,3-diamine;

N^1 -(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)- N^3,N^3 -dimethyl- N^1 -(piperidin-4-ylmethyl)propane-1,3-diamine;
 N^1 -(2-(4-Methoxyphenyl)quinolin-4-yl)- N^3 -((1-methyl-1H-imidazol-5-yl)methyl)propane-1,3-diamine;
 N -(3-(Hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;
 N^1 -((6-Aminopyridin-3-yl)methyl)- N^3 -(2-(4-methoxyphenyl)-quinolin-4-yl)- N^1 -methylpropane-1,3-diamine;
1-(Dimethylamino)-3-((3-((2-(4-methoxyphenyl)quinolin-4-yl)-amino)propyl)(methylamino)propan-2-ol;
1-(3-((3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)-methylamino)propyl)piperidin-4-ol;
tert-butyl 5-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate;
 N^1 -((6-(dimethylamino)pyridin-3-yl)methyl)- N^3 -(2-(4-methoxyphenyl)quinolin-4-yl)- N^1 -methyl propane-1,3-diamine;
 N^1 -(3-aminopropyl)- N^1 -methyl- N^3 -(2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;
 N^1 -(2-(4-methoxyphenyl)quinolin-4-yl)- N^3 -methyl- N^3 -((1-methylpiperidin-4-yl)methyl)propane-1,3-diamine;
 N^1 -(2-(4-methoxyphenyl)quinolin-4-yl)- N^3 -methyl- N^3 -(2-(piperidin-2-yl)ethyl)propane-1,3-diamine;
tert-Butyl (2-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)octahydrocyclopenta[c]pyrrol-4-yl)carbamate;
 N^1 -(2-(4-Methoxyphenyl)quinolin-4-yl)- N^3 -(octahydrocyclopenta[c]pyrrol-4-yl)propane-1,3-diamine;
 N -(3-(4-Aminohexahydrocyclopenta[c]pyrrol-2(1H)-yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

tert-Butyl 2-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)hexahydro-1H-pyrrolo[3,4-c]pyridine-5(6H)-carboxylate;

N-(3-(Hexahydro-1H-pyrrolo[3,4-c]pyridin-2(3H)-yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

tert-Butyl 4-((3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)amino)hexahydrocyclopenta[c] pyrrole-2(1H)-carboxylate;

N¹-((1-(Cyclopropylmethyl)piperidin-4-yl)methyl)-N³-(2-(4-methoxyphenyl)quinolin-4-yl)-N¹-methyl propane-1,3-diamine;

N-(2-(1-(3-Aminopropyl)piperidin-2-yl)ethyl)-2-(4-methoxyphenyl)quinolin-4-amine;

N¹-(1-(4-Fluorobenzyl)piperidin-4-yl)-N³-(2-(4-methoxyphenyl)quinolin-4-yl)propane-1,3-diamine;

tert-Butyl 6-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)-2,6-diazaspiro[3.4]octane-2-carboxylate;

N-(3-(2,6-Diazaspiro[3.4]octan-6-yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

2-(4-Methoxyphenyl)-N-(3-(4-methyl-1,4-diazepan-1-yl)propyl)quinolin-4-amine;

tert-Butyl 2-(2-((3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)amino)ethyl)piperidine-1-carboxylate;

N¹-(2-(4-methoxyphenyl)quinolin-4-yl)-N³-(2-(piperidin-2-yl)ethyl)propane-1,3-diamine;

N-(3-(4-(3-Aminopropyl)piperazin-1-yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

tert-Butyl 4-{[(3-{[2-(4-methoxyphenyl)quinolin-4-yl]amino}propyl)(methyl)amino]methyl} piperidine-1-carboxylate;

N-(3-(N-Methyl-N-((piperidin-4-yl)methyl)amino)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

N-(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)-4-(2H-tetrazol-5-yl)benzenesulfonamide;

N¹-(4-(2H-Tetrazol-5-yl)phenyl)-N³-(2-(4-methoxyphenyl)quinolin-4-yl)propane-1,3-diamine;

(1-(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)piperidin-4-yl)methanol;

1-(Diethylamino)-3-((3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)amino)propan-2-ol;

N¹-(2-(4-Methoxyphenyl)quinolin-4-yl)-N³-((1-methyl-1H-pyrazol-5-yl)methyl)propane-1,3-diamine;

N¹-(2-(4-methoxyphenyl)quinolin-4-yl)-N³-(2-(pyridin-2-yl)ethyl)propane-1,3-diamine;

N¹-(2-(4-Methoxyphenyl)quinolin-4-yl)-N³-(4-(piperidin-1-yl)phenyl)propane-1,3-diamine;

N-((1-(3-Aminopropyl)piperidin-3-yl)methyl)-2-(4-methoxyphenyl)quinolin-4-amine;

N-(3-(2-(6-Methoxy-1H-indol-3-yl)ethylamino)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

tert-Butyl 4-{{[1-[(tert-butoxy)carbonyl]piperidin-4-yl]methyl}(3-{[2-(4-methoxyphenyl)-quinolin-4-yl]amino}propyl)amino]methyl}piperidine-1-carboxylate;

N-(3-(Bis((piperidin-4-yl)methyl)amino)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

N¹-(4-Methoxybenzyl)-N³-(2-(4-methoxyphenyl)quinolin-4-yl)-N¹-methylpropane-1,3-diamine;

tert-Butyl (3-((4-((2-(4-methoxyphenyl)quinolin-4-yl)amino)cyclohexyl)amino)propyl)carbamate;

tert-Butyl 4-{{[3-{[2-(4-methoxyphenyl)quinolin-4-yl]amino}propyl]amino]methyl}piperidine-1-carboxylate;

N¹-(2-(4-methoxyphenyl)quinolin-4-yl)-N³-(3-(pyridin-4-ylamino)propyl)propane-1,3-diamine;

2-(3-(4-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)piperidin-1-yl)propyl)isoindoline-1,3-dione;

2-(3-(3-(((2-(4-Methoxyphenyl)quinolin-4-yl)amino)methyl)piperidin-1-yl)propyl)isoindoline-1,3-dione;

N-(3-((3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)amino)propyl)methanesulfonamide;

2-(3-(2-(2-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)ethyl)piperidin-1-yl)propyl)isoindoline-1,3-dione;

N-(3-(Hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

2-(4-Methoxyphenyl)-N-(1'-methyl-[1,4'-bipiperidine]-4-yl)quinolin-4-amine;

N¹-(2-Benzyl-octahydrocyclopenta[c]pyrrol-4-yl)-N³-(2-(4-methoxyphenyl)quinolin-4-yl)propane-1,3-diamine;

N¹-((1-(Cyclopropylmethyl)piperidin-4-yl)methyl)-N³-(2-(4-methoxyphenyl)quinolin-4-yl)propane-1,3-diamine;

1-(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)piperidine-4-carboxamide;

2-(4-Methoxyphenyl)-N-(3-(4-methylpiperazin-1-yl)propyl)quinolin-4-amine;

2-(4-Methoxyphenyl)-N-(2-(4-methylpiperazin-1-yl)ethyl)quinolin-4-amine;

2-(4-Methoxyphenyl)-N-(3-morpholinopropyl)quinolin-4-amine;

2-(7-Amino-4-methyl-2-oxo-2H-chromen-3-yl)-N-(3-((3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)(methyl)amino)propyl)acetamide;

5-(dimethylamino)-N-{3-[(3-{[2-(4-methoxyphenyl)quinolin-4-yl]amino}propyl)(methyl)amino]propyl}naphthalene-1-sulfonamide;

cis-N¹-(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)cyclobutane-1,3-diamine;

trans-N¹-(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)cyclobutane-1,3-diamine;

trans-*N*¹-(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)cyclohexane-1,4-diamine;
*N*¹-(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;
cis-*N*¹-(2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)cyclobutane-1,3-diamine;
*N*¹-(2-(4-(5,6-dihydropyrrolo[3,4-*c*]pyrazol-2(4*H*)-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;
cis-*N*¹-(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)cyclohexane-1,4-diamine;
*N*¹-(2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;
*N*¹-(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
*N*¹-(3-aminopropyl)-*N*¹-methyl-*N*³-(2-(3-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;
*N*¹-(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)cyclohexane-1,4-diamine;
*N*¹-(2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)cyclohexane-1,4-diamine;
2-amino-1-(4-(4-(4-((3-(dimethylamino)propyl)amino)quinolin-2-yl)phenyl)piperazin-1-yl)-3-methylbutan-1-one;
2-amino-1-(4-(4-(4-((3-(dimethylamino)propyl)amino)quinolin-2-yl)phenyl)piperazin-1-yl)propan-1-one;
*N*¹-(2-(1-(1-methylpiperidin-4-yl)-1*H*-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine;
*N*¹-(3-aminopropyl)-*N*³-(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)-*N*¹-methylpropane-1,3-diamine;
*N*¹-(2-(4-(piperidin-4-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;
*N*¹-(2-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine;
trans-*N*¹-(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)cyclobutane-1,3-diamine;

N^1,N^1 -dimethyl- N^3 -(2-(3-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;
 N^1,N^1 -dimethyl- N^3 -(2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;
 N^1 -(2-(1-(2-(pyrrolidin-1-yl)ethyl)-1*H*-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine;
trans- N^1 -(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)cyclohexane-1,4-diamine;
 N -(1-(4-aminocyclohexyl)piperidin-4-yl)-2-(4-methoxyphenyl)quinolin-4-amine;
 N^1 -(6-fluoro-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)- N^3,N^3 -dimethylpropane-1,3-diamine;
 N -(1-(3-aminopropyl)piperidin-4-yl)-2-(4-methoxyphenyl)quinolin-4-amine;
cis- N^1 -(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)cyclohexane-1,4-diamine;
2-amino- N -(1-((1-(4-(4-((3-(dimethylamino)propyl)amino)quinolin-2-yl)phenyl)piperazin-1-yl)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-3-methylbutanamide;
 N^1,N^1 -dimethyl- N^3 -(2-(1-(1-methylpiperidin-4-yl)-1*H*-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine;
 N^1 -(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)- N^3,N^3 -dimethylpropane-1,3-diamine;
 N^1 -(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)propane-1,3-diamine;
 N^1,N^1 -dimethyl- N^3 -(2-(4-(4-methylpiperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;
2-amino- N -(1-(4-(4-((3-(dimethylamino)propyl)amino)quinolin-2-yl)phenyl)piperazin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-methylbutanamide;
cis- N^1 -(2-(4-methoxyphenyl)quinolin-4-yl)cyclobutane-1,3-diamine;
 N^1 -([2,6'-biquinolin]-4-yl)propane-1,3-diamine;

4-(4-(4-((3-(dimethylamino)propyl)amino)quinolin-2-yl)phenyl)-1-methylpiperazin-2-one;

N^1 -(2-(piperidin-4-yl)quinolin-4-yl)propane-1,3-diamine;

N^1 -(2-(2,3-dihydrobenzofuran-5-yl)quinolin-4-yl)propane-1,3-diamine;

N^1 -(2-(4-(methoxy- d_3)phenyl)quinolin-4-yl)propane-1,3-diamine;

N^1 -([2,6'-biquinolin]-4-yl)- N^3,N^3 -dimethylpropane-1,3-diamine;

N^1 -(2-(4-methoxyphenyl)quinolin-4-yl)cyclobutane-1,3-diamine;

N^1 -(2-(1,2,3,6-tetrahydropyridin-4-yl)quinolin-4-yl)propane-1,3-diamine;

N^1 -(2-(4-methoxyphenyl)quinolin-4-yl)cyclohexane-1,4-diamine;

2-(4-methoxyphenyl)- N -(piperidin-4-yl)quinolin-4-amine;

N^1 -(2-(4-(methoxy- d_3)phenyl)quinolin-4-yl)- N^3,N^3 -dimethylpropane-1,3-diamine;

N^1 -(2-(benzofuran-5-yl)quinolin-4-yl)- N^3,N^3 -dimethylpropane-1,3-diamine;

N^1 -(2-(1-methyl-1*H*-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine;

N^1 -(2-(1-(azetidin-3-yl)-1*H*-pyrazol-4-yl)quinolin-4-yl)- N^3,N^3 -dimethylpropane-1,3-diamine;

N^1 -(2-(1-cyclopropyl-1*H*-pyrazol-4-yl)quinolin-4-yl)- N^3,N^3 -dimethylpropane-1,3-diamine;

N^1 -(2-(cyclohex-1-en-1-yl)quinolin-4-yl)propane-1,3-diamine;

(*S*)-2-amino- N -(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)- N -methylpropanamide;

N^1 -(2-(4-methoxyphenyl)quinolin-4-yl)- N^3,N^3 -bis(methyl- d_3)propane-1,3-diamine;

N^1 -(2-(furan-2-yl)quinolin-4-yl)propane-1,3-diamine;

N^1 -(5-fluoro-2-(4-methoxyphenyl)quinolin-4-yl)- N^3,N^3 -dimethylpropane-1,3-diamine;

N^1 -(2-(1-(2-morpholinoethyl)-1*H*-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine;

3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propan-1-ol;
*N*¹-(2-(2-methoxypyrimidin-5-yl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
*N*¹,*N*¹-dimethyl-*N*³-(2-methylquinolin-4-yl)propane-1,3-diamine;
 3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)-*N,N*-dimethylpropanamide;
*N*¹-(2-(6-methoxypyridin-3-yl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
*N*¹-(2,2-difluoro-6-(4-methoxyphenyl)-[1,3]dioxolo[4,5-*g*]quinolin-8-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
N-(4,4-difluorocyclohexyl)-2-(4-methoxyphenyl)quinolin-4-amine;
tert-butyl 3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propanoate;
*N*¹-(6-methoxy-2-(trifluoromethyl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
*N*¹-(6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
 2-cyclohexyl-*N*-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-amine;
*N*¹-(3-aminopropyl)-*N*³-(6,7-dimethoxyquinolin-4-yl)-*N*¹-methylpropane-1,3-diamine;
 6-methoxy-*N*-(1-methylpiperidin-4-yl)-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-amine;
*N*¹-(6,7-dimethoxyquinolin-4-yl)-*N*³,*N*³-diethylpropane-1,3-diamine;
 6,7-dimethoxy-*N*-(1'-methyl-[1,4'-bipiperidin]-4-yl)quinolin-4-amine;
*N*¹-(3-aminopropyl)-*N*³-(7-chloroquinolin-4-yl)-*N*¹-methylpropane-1,3-diamine;
*N*¹-(3-aminopropyl)-*N*³-(2-(4-(dimethylamino)phenyl)quinolin-4-yl)-*N*¹-methylpropane-1,3-diamine,
 an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

29. A composition comprising an effective amount of at least one compound according to claim 1.

30. The composition according to claim 29, further comprising at least one excipient.

31. The composition according to claim 30, wherein the at least one compound is at least one selected from the group consisting of:

N^1 -(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)- N^1,N^3,N^3 -trimethylpropane-1,3-diamine;

2-(4-Methoxyphenyl)-N-(3-{methyl[3-(methylamino)propyl]-amino}propyl)quinolin-4-amine;

N^1 -(3-Aminopropyl)- N^3 -(2-(4-methoxyphenyl)quinolin-4-yl)- N^1 -methylpropane-1,3-diamine;

N^1 -(2-(4-Methoxyphenyl)quinolin-4-yl)- N^3 -(3-(piperidin-1-yl)propyl)propane-1,3-diamine;

N^1 -(2-(4-methoxyphenyl)quinolin-4-yl)- N^3 -methyl- N^3 -(3-(piperidin-1-yl)propyl)propane-1,3-diamine;

tert-Butyl N -{3-[(3-{[2-(4-methoxyphenyl)quinolin-4yl]amino}propyl)amino]propyl} carbamate;

N^1 -(3-aminopropyl)- N^3 -(5-fluoro-2-(4-methoxyphenyl)quinolin-4-yl)- N^1 -methylpropane-1,3-diamine;

N -{3-[(3-Aminopropyl)amino]propyl}-2-(4-methoxyphenyl)quinolin-4-amine;

N^1 -(3-Aminopropyl)- N^3 -(6-methoxy-2-(4-methoxyphenyl)quinolin-4-yl)- N^1 -methylpropane-1,3-diamine;

N^1 -(3-Aminopropyl)- N^3 -(2-(2-methyl-4-methoxyphenyl)quinolin-4-yl)- N^1 -methylpropane-1,3-diamine;

N¹-(3-Aminopropyl)-N³-(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)-N¹-methylpropane-1,3-diamine;

N¹-(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)-N¹,N⁴-dimethylbutane-1,4-diamine;

N¹-(2-fluoroethyl)-N³-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)-N¹,N³-dimethylpropane-1,3-diamine;

3-(((3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)amino)-propan-1-ol;

N-(3-(3-methoxypropylamino)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

N-(3-(2-(4-Methoxyphenyl)quinolin-4-ylamino)propyl)-N-(3-aminopropyl)acetamide;

N¹-(Cyclopropylmethyl)-N¹-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)-N³,N³-dimethyl propane-1,3-diamine:

tert-Butyl 3-(((3-(dimethylamino)propyl)(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl) amino)methyl)azetidine-1-carboxylate;

tert-Butyl 4-(((3-(dimethylamino)propyl)(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl) amino)methyl)piperidine-1-carboxylate:

N¹-(Azetidin-3-ylmethyl)-N¹-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)-N³,N³-dimethylpropane-1,3-diamine;

N¹-(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)-N³,N³-dimethyl-N¹-(piperidin-4-ylmethyl)propane-1,3-diamine;

N¹-(2-(4-Methoxyphenyl)quinolin-4-yl)-N³-((1-methyl-1H-imidazol-5-yl)methyl)propane-1,3-diamine;

N-(3-(Hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

N¹-((6-Aminopyridin-3-yl)methyl)-N³-(2-(4-methoxyphenyl)-quinolin-4-yl)-N¹-methylpropane-1,3-diamine;

1-(Dimethylamino)-3-((3-((2-(4-methoxyphenyl)quinolin-4-yl)-amino)propyl)(methyl)amino)propan-2-ol;

1-(3-((3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)-methylamino)propyl)piperidin-4-ol;

tert-butyl 5-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)hexahydro-pyrrolo[3,4-c]pyrrole-2(1H)-carboxylate;

N¹-((6-(dimethylamino)pyridin-3-yl)methyl)-N³-(2-(4-methoxyphenyl)quinolin-4-yl)-N¹-methyl propane-1,3-diamine;

N¹-(3-aminopropyl)-N¹-methyl-N³-(2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;

N¹-(2-(4-methoxyphenyl)quinolin-4-yl)-N³-methyl-N³-((1-methylpiperidin-4-yl)methyl)propane-1,3-diamine;

N¹-(2-(4-methoxyphenyl)quinolin-4-yl)-N³-methyl-N³-(2-(piperidin-2-yl)ethyl)propane-1,3-diamine;

tert-Butyl (2-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)octahydrocyclopenta[c]pyrrol-4-yl)carbamate;

N¹-(2-(4-Methoxyphenyl)quinolin-4-yl)-N³-(octahydrocyclopenta[c]pyrrol-4-yl)propane-1,3-diamine;

N-(3-(4-Aminohexahydrocyclopenta[c]pyrrol-2(1H)-yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

tert-Butyl 2-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)hexahydro-1H-pyrrolo[3,4-c]pyridine-5(6H)-carboxylate;

N-(3-(Hexahydro-1H-pyrrolo[3,4-c]pyridin-2(3H)-yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

tert-Butyl 4-((3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)amino)hexahydrocyclopenta[c] pyrrole-2(1H)-carboxylate;

N¹-((1-(Cyclopropylmethyl)piperidin-4-yl)methyl)-N³-(2-(4-methoxyphenyl)quinolin-4-yl)-N¹-methyl propane-1,3-diamine;

N-(2-(1-(3-Aminopropyl)piperidin-2-yl)ethyl)-2-(4-methoxyphenyl)quinolin-4-amine;

N^1 -(1-(4-Fluorobenzyl)piperidin-4-yl)- N^3 -(2-(4-methoxyphenyl)quinolin-4-yl)propane-1,3-diamine:
 tert-Butyl 6-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)-2,6-diazaspiro[3.4]octane-2-carboxylate;
 N -(3-(2,6-Diazaspiro[3.4]octan-6-yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine:
 2-(4-Methoxyphenyl)- N -(3-(4-methyl-1,4-diazepan-1-yl)propyl)quinolin-4-amine:
 tert-Butyl 2-(2-((3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)amino)ethyl)piperidine-1-carboxylate;
 N^1 -(2-(4-methoxyphenyl)quinolin-4-yl)- N^3 -(2-(piperidin-2-yl)ethyl)propane-1,3-diamine;
 N -(3-(4-(3-Aminopropyl)piperazin-1-yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;
 tert-Butyl 4-{[(3-{[2-(4-methoxyphenyl)quinolin-4-yl]amino}propyl)(methyl)amino]methyl} piperidine-1-carboxylate;
 N -(3-(N -Methyl- N -((piperidin-4-yl)methyl)amino)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;
 N -(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)-4-(2H-tetrazol-5-yl)benzenesulfonamide;
 N^1 -(4-(2H-Tetrazol-5-yl)phenyl)- N^3 -(2-(4-methoxyphenyl)quinolin-4-yl)propane-1,3-diamine;
 (1-(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)piperidin-4-yl)methanol;
 1-(Diethylamino)-3-((3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)amino)propan-2-ol;
 N^1 -(2-(4-Methoxyphenyl)quinolin-4-yl)- N^3 -((1-methyl-1H-pyrazol-5-yl)methyl)propane-1,3-diamine;
 N^1 -(2-(4-methoxyphenyl)quinolin-4-yl)- N^3 -(2-(pyridin-2-yl)ethyl)propane-1,3-diamine;

N¹-(2-(4-Methoxyphenyl)quinolin-4-yl)-N³-(4-(piperidin-1-yl)phenyl)propane-1,3-diamine;

N-((1-(3-Aminopropyl)piperidin-3-yl)methyl)-2-(4-methoxyphenyl)quinolin-4-amine;

N-(3-(2-(6-Methoxy-1H-indol-3-yl)ethylamino)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

tert-Butyl 4-{{{1-[(tert-butoxy)carbonyl]piperidin-4-yl}methyl}(3-{[2-(4-methoxyphenyl)-quinolin-4-yl]amino}propyl)amino)methyl}piperidine-1-carboxylate;

N-(3-(Bis((piperidin-4-yl)methyl)amino)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

N¹-(4-Methoxybenzyl)-N³-(2-(4-methoxyphenyl)quinolin-4-yl)-N¹-methylpropane-1,3-diamine;

tert-Butyl (3-((4-((2-(4-methoxyphenyl)quinolin-4-yl)amino)cyclohexyl)amino)propyl)carbamate;

tert-Butyl 4-{{{3-([2-(4-methoxyphenyl)quinolin-4-yl]amino}propyl)amino)methyl}piperidine-1-carboxylate;

N¹-(2-(4-methoxyphenyl)quinolin-4-yl)-N³-(3-(pyridin-4-ylamino)propyl)propane-1,3-diamine;

2-(3-(4-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)piperidin-1-yl)propyl)isoindoline-1,3-dione;

2-(3-(3-(((2-(4-Methoxyphenyl)quinolin-4-yl)amino)methyl)piperidin-1-yl)propyl)isoindoline-1,3-dione;

N-(3-((3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)amino)propyl)methanesulfonamide;

2-(3-(2-(2-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)ethyl)piperidin-1-yl)propyl)isoindoline-1,3-dione;

N-(3-(Hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine;

2-(4-Methoxyphenyl)-N-(1'-methyl-[1,4'-bipiperidine]-4-yl)quinolin-4-amine;
N¹-(2-Benzyl-octahydrocyclopenta[c]pyrrol-4-yl)-N³-(2-(4-methoxyphenyl)quinolin-4-yl)propane-1,3-diamine;
N¹-((1-(Cyclopropylmethyl)piperidin-4-yl)methyl)-N³-(2-(4-methoxyphenyl)quinolin-4-yl)propane-1,3-diamine;
1-(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)piperidine-4-carboxamide;
2-(4-Methoxyphenyl)-N-(3-(4-methylpiperazin-1-yl)propyl)quinolin-4-amine;
2-(4-Methoxyphenyl)-N-(2-(4-methylpiperazin-1-yl)ethyl)quinolin-4-amine;
2-(4-Methoxyphenyl)-N-(3-morpholinopropyl)quinolin-4-amine;
2-(7-Amino-4-methyl-2-oxo-2H-chromen-3-yl)-N-(3-((3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)(methyl)amino)propyl)acetamide;
5-(dimethylamino)-N-{3-[(3-[(2-(4-methoxyphenyl)quinolin-4-yl]amino)propyl)(methyl)amino]propyl}naphthalene-1-sulfonamide,
cis-N¹-(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)cyclobutane-1,3-diamine;
trans-N¹-(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)cyclobutane-1,3-diamine;
trans-N¹-(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)cyclohexane-1,4-diamine;
N¹-(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;
cis-N¹-(2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)cyclobutane-1,3-diamine;
N¹-(2-(4-(5,6-dihydropyrrolo[3,4-*c*]pyrazol-2(4*H*)-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;
cis-N¹-(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)cyclohexane-1,4-diamine;
N¹-(2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;
N¹-(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)-N³,N³-dimethylpropane-1,3-diamine;

*N*¹-(3-aminopropyl)-*N*¹-methyl-*N*³-(2-(3-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;

*N*¹-(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)cyclohexane-1,4-diamine;

*N*¹-(2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)cyclohexane-1,4-diamine;

2-amino-1-(4-(4-(4-((3-(dimethylamino)propyl)amino)quinolin-2-yl)phenyl)piperazin-1-yl)-3-methylbutan-1-one;

2-amino-1-(4-(4-(4-((3-(dimethylamino)propyl)amino)quinolin-2-yl)phenyl)piperazin-1-yl)propan-1-one;

*N*¹-(2-(1-(1-methylpiperidin-4-yl)-1*H*-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine;

*N*¹-(3-aminopropyl)-*N*³-(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)-*N*¹-methylpropane-1,3-diamine;

*N*¹-(2-(4-(piperidin-4-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;

*N*¹-(2-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine;

*trans-N*¹-(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)cyclobutane-1,3-diamine;

*N*¹,*N*¹-dimethyl-*N*³-(2-(3-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;

*N*¹,*N*¹-dimethyl-*N*³-(2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;

*N*¹-(2-(1-(2-(pyrrolidin-1-yl)ethyl)-1*H*-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine;

*trans-N*¹-(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)cyclohexane-1,4-diamine;

N-(1-(4-aminocyclohexyl)piperidin-4-yl)-2-(4-methoxyphenyl)quinolin-4-amine;

*N*¹-(6-fluoro-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;

N-(1-(3-aminopropyl)piperidin-4-yl)-2-(4-methoxyphenyl)quinolin-4-amine;

cis-*N*¹-(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)cyclohexane-1,4-diamine;
2-amino-*N*-(1-((1-(4-(4-(4-((3-(dimethylamino)propyl)amino)quinolin-2-yl)phenyl)piperazin-1-yl)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-3-methylbutanamide;

*N*¹,*N*¹-dimethyl-*N*³-(2-(1-(1-methylpiperidin-4-yl)-1*H*-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine;

*N*¹-(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;

*N*¹-(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)propane-1,3-diamine;

*N*¹,*N*¹-dimethyl-*N*³-(2-(4-(4-methylpiperazin-1-yl)phenyl)quinolin-4-yl)propane-1,3-diamine;

2-amino-*N*-(1-(4-(4-(4-((3-(dimethylamino)propyl)amino)quinolin-2-yl)phenyl)piperazin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-methylbutanamide;

cis-*N*¹-(2-(4-methoxyphenyl)quinolin-4-yl)cyclobutane-1,3-diamine;

*N*¹-([2,6'-biquinolin]-4-yl)propane-1,3-diamine;

4-(4-(4-((3-(dimethylamino)propyl)amino)quinolin-2-yl)phenyl)-1-methylpiperazin-2-one;

*N*¹-(2-(piperidin-4-yl)quinolin-4-yl)propane-1,3-diamine;

*N*¹-(2-(2,3-dihydrobenzofuran-5-yl)quinolin-4-yl)propane-1,3-diamine;

*N*¹-(2-(4-(methoxy-*d*₃)phenyl)quinolin-4-yl)propane-1,3-diamine;

*N*¹-([2,6'-biquinolin]-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;

*N*¹-(2-(4-methoxyphenyl)quinolin-4-yl)cyclobutane-1,3-diamine;

*N*¹-(2-(1,2,3,6-tetrahydropyridin-4-yl)quinolin-4-yl)propane-1,3-diamine;

*N*¹-(2-(4-methoxyphenyl)quinolin-4-yl)cyclohexane-1,4-diamine;

2-(4-methoxyphenyl)-*N*-(piperidin-4-yl)quinolin-4-amine;

*N*¹-(2-(4-(methoxy-*d*₃)phenyl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;

*N*¹-(2-(benzofuran-5-yl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
*N*¹-(2-(1-methyl-1*H*-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine;
*N*¹-(2-(1-(azetidin-3-yl)-1*H*-pyrazol-4-yl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
*N*¹-(2-(1-cyclopropyl-1*H*-pyrazol-4-yl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
*N*¹-(2-(cyclohex-1-en-1-yl)quinolin-4-yl)propane-1,3-diamine;
(*S*)-2-amino-*N*-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)-*N*-methylpropanamide;
*N*¹-(2-(4-methoxyphenyl)quinolin-4-yl)-*N*³,*N*³-bis(methyl-*d*₃)propane-1,3-diamine;
*N*¹-(2-(furan-2-yl)quinolin-4-yl)propane-1,3-diamine;
*N*¹-(5-fluoro-2-(4-methoxyphenyl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
*N*¹-(2-(1-(2-morpholinoethyl)-1*H*-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine;
3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propan-1-ol;
*N*¹-(2-(2-methoxypyrimidin-5-yl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
*N*¹,*N*¹-dimethyl-*N*³-(2-methylquinolin-4-yl)propane-1,3-diamine;
3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)-*N*,*N*-dimethylpropanamide;
*N*¹-(2-(6-methoxypyridin-3-yl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
*N*¹-(2,2-difluoro-6-(4-methoxyphenyl)-[1,3]dioxolo[4,5-*g*]quinolin-8-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;
N-(4,4-difluorocyclohexyl)-2-(4-methoxyphenyl)quinolin-4-amine;
tert-butyl 3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propanoate;
*N*¹-(6-methoxy-2-(trifluoromethyl)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;

*N*¹-(6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine,

*N*¹-(6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-yl)-*N*³,*N*³-dimethylpropane-1,3-diamine;

2-cyclohexyl-*N*-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-amine;

*N*¹-(3-aminopropyl)-*N*³-(6,7-dimethoxyquinolin-4-yl)-*N*¹-methylpropane-1,3-diamine;

6-methoxy-*N*-(1-methylpiperidin-4-yl)-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-amine;

*N*¹-(6,7-dimethoxyquinolin-4-yl)-*N*³,*N*³-diethylpropane-1,3-diamine;


6,7-dimethoxy-*N*-(1'-methyl-[1,4'-bipiperidin]-4-yl)quinolin-4-amine;

*N*¹-(3-aminopropyl)-*N*³-(7-chloroquinolin-4-yl)-*N*¹-methylpropane-1,3-diamine;

*N*¹-(3-aminopropyl)-*N*³-(2-(4-(dimethylamino)phenyl)quinolin-4-yl)-*N*¹-methylpropane-1,3-diamine;

an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof.

32. A method for treating or preventing a disease that involves TDP-43, the method comprising administering to a subject an effective amount of at least one compound having formula (I):



an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug or a complex thereof, wherein:

X¹ is selected from the group consisting of nitrogen and CH;

R^{1a} is selected from the group consisting of hydrogen, halogen, C₁₋₂₀ linear alkyl, C₃₋₂₀ branched alkyl, C₁₋₂₀ linear heteroalkyl, C₃₋₂₀ branched heteroalkyl, each of which except hydrogen and halogen are optionally substituted;

R^{1b} is selected from the group consisting of hydrogen, halogen, C₁₋₂₀ linear alkyl, C₃₋₂₀ branched alkyl, C₁₋₂₀ linear heteroalkyl, C₃₋₂₀ branched heteroalkyl, each of which except hydrogen and halogen are optionally substituted;


R^{1c} is selected from the group consisting of hydrogen, halogen, C₁₋₂₀ linear alkyl, C₃₋₂₀ branched alkyl, C₁₋₂₀ linear heteroalkyl, C₃₋₂₀ branched heteroalkyl, each of which except hydrogen and halogen are optionally substituted; and

R^{1d} is selected from the group consisting of hydrogen, halogen, C₁₋₂₀ linear alkyl, C₃₋₂₀ branched alkyl, C₁₋₂₀ linear heteroalkyl, C₃₋₂₀ branched heteroalkyl, each of which except hydrogen and halogen are optionally substituted.

R² is a substituted or unsubstituted C_{1-C20} linear, branched, or cyclic organic group including at least one nitrogen; and

R⁴ is a hydrogen, halogen, a hydroxyl group, a cyano group, a nitro group, a substituted or unsubstituted C_{0-C10} amino group, a substituted or unsubstituted C_{1-C10} alkyl group, a substituted or unsubstituted C_{2-C10} alkenyl group, a substituted or unsubstituted C_{2-C10} alkynyl group, and a substituted or unsubstituted C_{1-C10} alkoxy group, a substituted or unsubstituted C_{3-C10} cycloalkyl group, a substituted or unsubstituted C_{2-C10} heterocycloalkyl group, a substituted or unsubstituted C_{3-C10} cycloalkenyl group, a substituted or unsubstituted C_{2-C10} heterocycloalkenyl group, a substituted or unsubstituted C_{6-C20} aryl group, a substituted or unsubstituted C_{6-C20} aryloxy group, a substituted or unsubstituted C_{6-C20} arylthio group, a substituted or unsubstituted C_{2-C20} heteroaryl group, a substituted or unsubstituted C_{2-C20} heteroaryloxy group, or a substituted or unsubstituted C_{2-C20} heteroarylthio group,

provided that the following compounds in which each hydrogen is a proton are excluded:



33. The method of claim 32, wherein the at least one compound is administered in a composition further comprising at least one excipient.

34. The method of claim 33, wherein the diseases that involves TDP-43 is selected from the group consisting of ALS, FTLD, CTE, hippocampal sclerosis of aging (CARTS), Alzheimer's disease, and Alzheimer's disease related disorders.

35. A method for treating or preventing a disease associated with TDP-43 proteinopathies, the method comprising administering to a subject an effective amount of at least one compound according to claim 1.

36. The method of claim 35, wherein the at least one compound is administered in a composition further comprising at least one excipient.

37. A method for treating or preventing diseases that involve excess amounts of TDP-43 in the cytosol, the method comprising administering to a subject an effective amount of at least one compound according to claim 1.

38. The method of claim 37, wherein the at least one compound is administered in a composition further comprising at least one excipient.

39. The method of use of the TDP-43 binders of the present invention as positron emission tomography (PET) imaging agents, wherein the method comprises administering to a subject an effective amount of an isotopically labeled compound according to claim 1.

40. The method of use of the TDP-43 binders of the present invention as single-photon emission computed tomography (SPECT) imaging agents, wherein the method comprises administering to a subject an effective amount of an isotopically labeled compound according to claim 1.